Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized, Controlled Trial of High-Dose Influenza Vaccine Among Frail Residents of Long-Term Care Facilities</title><author><name sortKey="Nace, David A" sort="Nace, David A" uniqKey="Nace D" first="David A." last="Nace">David A. Nace</name><affiliation><nlm:aff id="af1"><addr-line>Division of Geriatric Medicine</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lin, Chyongchiou Jeng" sort="Lin, Chyongchiou Jeng" uniqKey="Lin C" first="Chyongchiou Jeng" last="Lin">Chyongchiou Jeng Lin</name><affiliation><nlm:aff id="af2"><addr-line>Department of Family Medicine</addr-line>,<institution>University of Pittsburgh</institution>,<addr-line>Pennsylvania</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ross, Ted M" sort="Ross, Ted M" uniqKey="Ross T" first="Ted M." last="Ross">Ted M. Ross</name><affiliation><nlm:aff id="af3"><institution>Vaccine and Gene Therapy Institute of Florida</institution>,<addr-line>Port Saint Lucie</addr-line></nlm:aff></affiliation></author><author><name sortKey="Saracco, Stacey" sort="Saracco, Stacey" uniqKey="Saracco S" first="Stacey" last="Saracco">Stacey Saracco</name><affiliation><nlm:aff id="af1"><addr-line>Division of Geriatric Medicine</addr-line></nlm:aff></affiliation></author><author><name sortKey="Churilla, Roberta M" sort="Churilla, Roberta M" uniqKey="Churilla R" first="Roberta M." last="Churilla">Roberta M. Churilla</name><affiliation><nlm:aff id="af1"><addr-line>Division of Geriatric Medicine</addr-line></nlm:aff></affiliation></author><author><name sortKey="Zimmerman, Richard K" sort="Zimmerman, Richard K" uniqKey="Zimmerman R" first="Richard K." last="Zimmerman">Richard K. Zimmerman</name><affiliation><nlm:aff id="af2"><addr-line>Department of Family Medicine</addr-line>,<institution>University of Pittsburgh</institution>,<addr-line>Pennsylvania</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">25525051</idno><idno type="pmc">4539906</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539906</idno><idno type="RBID">PMC:4539906</idno><idno type="doi">10.1093/infdis/jiu622</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">000104</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000104</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Randomized, Controlled Trial of High-Dose Influenza Vaccine Among Frail Residents of Long-Term Care Facilities</title><author><name sortKey="Nace, David A" sort="Nace, David A" uniqKey="Nace D" first="David A." last="Nace">David A. Nace</name><affiliation><nlm:aff id="af1"><addr-line>Division of Geriatric Medicine</addr-line></nlm:aff></affiliation></author><author><name sortKey="Lin, Chyongchiou Jeng" sort="Lin, Chyongchiou Jeng" uniqKey="Lin C" first="Chyongchiou Jeng" last="Lin">Chyongchiou Jeng Lin</name><affiliation><nlm:aff id="af2"><addr-line>Department of Family Medicine</addr-line>,<institution>University of Pittsburgh</institution>,<addr-line>Pennsylvania</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ross, Ted M" sort="Ross, Ted M" uniqKey="Ross T" first="Ted M." last="Ross">Ted M. Ross</name><affiliation><nlm:aff id="af3"><institution>Vaccine and Gene Therapy Institute of Florida</institution>,<addr-line>Port Saint Lucie</addr-line></nlm:aff></affiliation></author><author><name sortKey="Saracco, Stacey" sort="Saracco, Stacey" uniqKey="Saracco S" first="Stacey" last="Saracco">Stacey Saracco</name><affiliation><nlm:aff id="af1"><addr-line>Division of Geriatric Medicine</addr-line></nlm:aff></affiliation></author><author><name sortKey="Churilla, Roberta M" sort="Churilla, Roberta M" uniqKey="Churilla R" first="Roberta M." last="Churilla">Roberta M. Churilla</name><affiliation><nlm:aff id="af1"><addr-line>Division of Geriatric Medicine</addr-line></nlm:aff></affiliation></author><author><name sortKey="Zimmerman, Richard K" sort="Zimmerman, Richard K" uniqKey="Zimmerman R" first="Richard K." last="Zimmerman">Richard K. Zimmerman</name><affiliation><nlm:aff id="af2"><addr-line>Department of Family Medicine</addr-line>,<institution>University of Pittsburgh</institution>,<addr-line>Pennsylvania</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">The Journal of Infectious Diseases</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><bold><italic>Background.</italic></bold> Despite vaccination, residents of long-term-care facilities (LTCFs) remain at high risk of influenza-related morbidity and mortality. More-effective vaccine options for this population are needed.</p><p><bold><italic>Methods.</italic></bold> We conducted a single-blinded, randomized, controlled trial comparing high-dose (HD) to standard-dose (SD) inactivated influenza vaccine (IIV) in 205 frail, elderly residents of LTCFs during the 2011–2012 and 2012–2013 influenza seasons. Hemagglutination inhibition (HI) antibody titers were measured at baseline and 30 and 180 days following vaccination.</p><p><bold><italic>Results.</italic></bold> A total of 187 subjects (91%) completed the study. The mean age was 86.7 years. Geometric mean titers (GMTs) were significantly higher (<italic>P</italic> < .05) at day 30 for HD recipients, compared with SD recipients, for all comparisons except influenza A(H1N1) during 2012–2013 (the HD formulation was noninferior to the SD formulation for influenza A[H1N1] during 2012–2013). GMTs for HD and SD recipients during 2011–2012 were as follows: influenza A(H1N1), 78 (95% confidence interval [CI], 45–136) and 27 (95% CI, 17–44), respectively; influenza A(H3N2), 26 (95% CI, 17–40) and 10 (95% CI, 7–15), respectively; and influenza B, 26 (95% CI, 19–35) and 14 (95% CI, 11–18), respectively. During 2012–2013, GMTs for HD and SD recipients were as follows: influenza A(H1N1), 46 (95% CI, 33–63) and 50 (95% CI, 37–67); influenza A(H3N2), 23 (95% CI, 18–31) and 14 (95% CI, 11–18), respectively; and influenza B, 26 (95% CI, 21–32) and 17 (95% CI, 14–22), respectively. GMTs were significantly higher at day 180 for HD recipients, compared with SD recipients, for influenza A(H3N2) in both years (<italic>P</italic> < .001).</p><p><bold><italic>Conclusions.</italic></bold> Among frail, elderly residents of LTCFs, HD influenza vaccine produced superior responses for all strains except influenza A(H1N1) in 2012–2013.</p><p><bold><italic>Clinical Trials Registration.</italic></bold> NCT01654224.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">J. Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">jid</journal-id><journal-id journal-id-type="hwp">jinfdis</journal-id><journal-title-group><journal-title>The Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">0022-1899</issn><issn pub-type="epub">1537-6613</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25525051</article-id><article-id pub-id-type="pmc">4539906</article-id><article-id pub-id-type="doi">10.1093/infdis/jiu622</article-id><article-id pub-id-type="publisher-id">jiu622</article-id><article-categories><subj-group subj-group-type="heading"><subject>Major Articles and Brief Reports</subject><subj-group subj-group-type="heading"><subject>Viruses</subject></subj-group></subj-group><series-title>Editor's choice</series-title></article-categories><title-group><article-title>Randomized, Controlled Trial of High-Dose Influenza Vaccine Among Frail Residents of Long-Term Care Facilities</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nace</surname><given-names>David A.</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Chyongchiou Jeng</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ross</surname><given-names>Ted M.</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Saracco</surname><given-names>Stacey</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Churilla</surname><given-names>Roberta M.</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zimmerman</surname><given-names>Richard K.</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><aff id="af1"><label>1</label><addr-line>Division of Geriatric Medicine</addr-line></aff><aff id="af2"><label>2</label><addr-line>Department of Family Medicine</addr-line>,<institution>University of Pittsburgh</institution>,<addr-line>Pennsylvania</addr-line></aff><aff id="af3"><label>3</label><institution>Vaccine and Gene Therapy Institute of Florida</institution>,<addr-line>Port Saint Lucie</addr-line></aff></contrib-group><author-notes><fn id="AN1" fn-type="con"><p>Presented in part: IDWeek 2013, San Francisco, California, 2–6 October 2013.</p></fn><corresp>Correspondence: David A. Nace, MD, MPH, Division of Geriatric Medicine, 3471 Fifth Ave, Ste 500, Pittsburgh, PA 15213 (<email>naceda@upmc.edu</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>15</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>6</month><year>2016</year></pub-date><pmc-comment> PMC Release delay is 12 months and
0 days and was based on the
<volume>211</volume><issue>12</issue><fpage>1915</fpage><lpage>1924</lpage><history><date date-type="received"><day>18</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>2</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: <email>journals.permissions@oup.com</email>.</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="jiu622.pdf"></self-uri><abstract><p><bold><italic>Background.</italic></bold> Despite vaccination, residents of long-term-care facilities (LTCFs) remain at high risk of influenza-related morbidity and mortality. More-effective vaccine options for this population are needed.</p><p><bold><italic>Methods.</italic></bold> We conducted a single-blinded, randomized, controlled trial comparing high-dose (HD) to standard-dose (SD) inactivated influenza vaccine (IIV) in 205 frail, elderly residents of LTCFs during the 2011–2012 and 2012–2013 influenza seasons. Hemagglutination inhibition (HI) antibody titers were measured at baseline and 30 and 180 days following vaccination.</p><p><bold><italic>Results.</italic></bold> A total of 187 subjects (91%) completed the study. The mean age was 86.7 years. Geometric mean titers (GMTs) were significantly higher (<italic>P</italic> < .05) at day 30 for HD recipients, compared with SD recipients, for all comparisons except influenza A(H1N1) during 2012–2013 (the HD formulation was noninferior to the SD formulation for influenza A[H1N1] during 2012–2013). GMTs for HD and SD recipients during 2011–2012 were as follows: influenza A(H1N1), 78 (95% confidence interval [CI], 45–136) and 27 (95% CI, 17–44), respectively; influenza A(H3N2), 26 (95% CI, 17–40) and 10 (95% CI, 7–15), respectively; and influenza B, 26 (95% CI, 19–35) and 14 (95% CI, 11–18), respectively. During 2012–2013, GMTs for HD and SD recipients were as follows: influenza A(H1N1), 46 (95% CI, 33–63) and 50 (95% CI, 37–67); influenza A(H3N2), 23 (95% CI, 18–31) and 14 (95% CI, 11–18), respectively; and influenza B, 26 (95% CI, 21–32) and 17 (95% CI, 14–22), respectively. GMTs were significantly higher at day 180 for HD recipients, compared with SD recipients, for influenza A(H3N2) in both years (<italic>P</italic> < .001).</p><p><bold><italic>Conclusions.</italic></bold> Among frail, elderly residents of LTCFs, HD influenza vaccine produced superior responses for all strains except influenza A(H1N1) in 2012–2013.</p><p><bold><italic>Clinical Trials Registration.</italic></bold> NCT01654224.</p></abstract><kwd-group><kwd>inactivated influenza vaccine</kwd><kwd>high-dose influenza vaccine</kwd><kwd>long-term care</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0001040 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0001040 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Amérique
|area= PittsburghV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.38. |  |